By Justin Yamashita. Benchtop, site, CRO. Three levels of basic and clinical research, explained without spin.

The Root Room is where we open the doors most people never walk through. Some of those doors are in research labs, trial sites, and FDA review rooms. Others are inside our own feeds and our own heads, because that is where the evidence first has to compete with the noise. Each issue, we step inside with the characters who live there.

This week, the room Debby is sitting in is her brother-in-law's living room. It is a Sunday. They are watching basketball. He has been on Threads. He is about to ruin the game.

He brought it up between the third and fourth quarter.

"There is a cure for cancer," he said. "Multiple cures. They have been sitting in labs for years. The pharmaceutical companies will not release them because cancer treatment is too profitable. A cured patient is a lost customer."

Debby felt the familiar pull. It had a logic to it. Cancer treatment costs hundreds of thousands of dollars. The companies that make the treatments are enormously profitable. Why would they want the disease to end?

In March, a post about a "newly declassified CIA document" started circulating across health and conspiracy networks. The post claimed the document proved that pharmaceutical companies have been suppressing cancer cures for decades. By the second week of April it had crossed into mainstream feeds. By the time Debby's brother-in-law saw it, it had been screenshotted, restitched into Reels, narrated by three different self-styled medical truth-tellers, and assembled into a 47-page PDF that nobody had read but many had downloaded.

She pulled out her phone. By the time she looked up, the algorithm had filled it. Echo had done the work. Videos with urgent music and cinema-grade thumbnails. Screenshots of studies with alarming titles she could not access. A doctor she had never heard of saying the cancer cure had been ready in 2017 and was buried.

Then Dr. Anecdote arrived in the comments. Dr. Anecdote always does. "My cousin's oncologist told him there was a cure they couldn't release. The company shut it down after a private meeting. He saw the email." The story is always vivid, always specific, always unverifiable.

Bias the Brain stayed quiet, doing what Bias does best. Bias did not argue with Debby. Bias whispered what she already wanted to be true. That the people in charge of medicine were not on her side. That she had every reason to believe a system that has, in fact, failed many people in well-documented ways.

These are the actual antagonists of this room. Not Debby. Echo does not care if Debby is right. Echo cares if Debby keeps watching. Dr. Anecdote does not care if Debby is informed. Dr. Anecdote cares that the next vivid story keeps her engaged. Bias does not need to convince. Bias only needs to nod.

Sam the Skeptic has been watching from the doorway. He does not start by telling Debby she is wrong. He starts by handing her something.

"Issue 003b," Sam says. "The toolkit. Question 9 first. What do independent experts with no stake in the outcome say? The suppressed cancer cure claim requires something very specific to be true: that every oncologist, every cancer researcher, every journal editor, every regulator, every NIH grant reviewer, and every government health agency in every country with an independent research establishment is participating in the suppression, or has been prevented from finding what has already been found. That is not a conspiracy. That is a coordination problem of a scale that has never existed in any documented human institution."

"And Question 6," Sam continues. "Am I seeing the full picture, or only part of the evidence? Cancer is not one disease. It is more than 200 distinct diseases driven by hundreds of different molecular events. A cure for cancer is like a key for all locks. The key the post is talking about does not exist in the form the post imagines, because the lock the post is imagining does not exist either."

Rooty the Researcher steps in next, carrying the data Sam will not pretend to know off the top of his head.

"The Philadelphia chromosome," Rooty says. "Discovered in 1960. Nobody knew what it meant for 13 years. Janet Rowley figured out the translocation in 1973. The molecular characterization of BCR-ABL took another decade. The drug, Gleevec, arrived in 2001. Forty-one years from observation to FDA approval. Every step is sitting in the public scientific record. The work was suppressed by exactly nobody. The work was just hard."

"Novartis did sit on the molecule for six years," Rooty adds. "But not because of a profit motive. They did not believe a kinase inhibitor could be selective enough to work, and they did not want to invest in it. A single oncologist named Brian Druker forced their hand. That is corporate inertia, scientific uncertainty, and one person who would not let go. Those are different problems with different solutions."

Debby is not impressed. "Of course they want me to believe the system works," she says. "That is exactly what they would tell me."

Sam nods. "That instinct is fair. Question 4 in the toolkit is the one for it: who funded this, and do they have a stake in the answer? The post Debby's brother-in-law is sharing has no funding disclosure at all. No author. No institutional affiliation. No corrections process. No journal. The Philadelphia chromosome story has all of those, openly, for sixty-five years. The asymmetry is the answer."

Debby is not convinced. She is not even close to convinced. She is doing what most people do when the toolkit first arrives: holding her position and looking for the next reason the toolkit does not apply.

That is the realistic place to start. Root to Rx does not exist to convert anyone in one issue. Root to Rx exists to put the toolkit in your hands so you can dig your way out, in your own time, on your own terms. We do not throw conclusions at you. We do not throw shovels at the people throwing shovels at us. We hand you the shovel and we step back.

Debby will be back. So will Sam. So will Echo, Dr. Anecdote, and the others. The Root Room has many functions. We will explore them as a community.

Next issue we open another door. The same scientist Rooty mentioned, the oncologist who would not let go, walks into the office of the company that owns the molecule. He is told no. He is told no for six years. We explore why, and what changed.

The Root Room story above is what evidence-evaluation looks like at the dinner table. What follows is the institutional version: the specific molecular biology of chromosomal translocations, why BCR-ABL is the protein that makes CML, and the structural reason kinase inhibitors were assumed to be impossible. This is the level of detail that lets you read a primary source rather than a press release.

If you have found this helpful, and would like to help more people become Rooted, please consider referring this newsletter to friends, family, or colleagues.

Chromosomes are linear DNA molecules wrapped around histone proteins and condensed into structures visible under a light microscope. Human somatic cells contain 46 chromosomes in 23 homologous pairs. The integrity of chromosome structure is maintained by multiple DNA repair pathways, including homologous recombination and non-homologous end joining.

A chromosomal translocation occurs when a segment of one chromosome breaks and reattaches to a different chromosome. The Philadelphia chromosome results from a reciprocal translocation between the long arms of chromosomes 9 and 22, designated t(9;22)(q34;q11). A segment of chromosome 9 containing the proto-oncogene ABL1 breaks and fuses to a region of chromosome 22 called BCR, the Breakpoint Cluster Region. The resulting derivative chromosome 22, shortened due to the gain of a smaller segment from chromosome 9, is the Philadelphia chromosome.

The fusion creates a novel chimeric gene, BCR-ABL1, which encodes a protein not present in any normal cell. The specific molecular weight of the fusion protein depends on the breakpoint location within BCR. In CML, the most common product is the p210 fusion protein, a 210-kilodalton tyrosine kinase that is constitutively active.

Tyrosine kinases are enzymes that catalyze the transfer of a phosphate group from ATP to tyrosine residues on target proteins. This phosphorylation event is a fundamental mechanism of cellular signaling: it changes the activity, localization, or binding partners of the target protein, transmitting information through the cell and ultimately regulating processes including proliferation, differentiation, and apoptosis.

Normal ABL1 is a non-receptor tyrosine kinase with tightly regulated activity. Its activation is transient and context-dependent. BCR-ABL is not regulated in this way. The BCR portion of the fusion protein contains oligomerization domains that cause BCR-ABL to dimerize and autophosphorylate constitutively, maintaining kinase activity regardless of upstream signals. The result is uncontrolled downstream signaling through multiple pathways, including RAS-MAPK, PI3K-AKT, and JAK-STAT, all of which promote cell survival and proliferation while inhibiting programmed cell death.

In CML, this constitutive BCR-ABL activity transforms a hematopoietic progenitor cell into a leukemic stem cell that produces an expanding clone of abnormal myeloid cells. The disease is characterized by three phases: chronic phase, in which the abnormal clone expands but retains some capacity for differentiation; accelerated phase; and blast crisis, in which the cells lose differentiation capacity entirely and the disease becomes acutely life-threatening within months.

By the late 1980s, BCR-ABL was well-characterized as the driver of CML. The logical therapeutic hypothesis was straightforward: inhibit BCR-ABL and you stop the signal driving the cancer. The scientific community largely rejected this hypothesis on chemical grounds.

Tyrosine kinases catalyze their reactions using the ATP-binding pocket, a conserved structural domain shared across hundreds of kinase family members. Any small molecule designed to occupy the ATP-binding pocket and thereby block kinase activity would need to discriminate between BCR-ABL's ATP pocket and the ATP pockets of the hundreds of other kinases that normal cells require to function. The selectivity required was widely considered chemically unachievable.

The concern was not theoretical. Early attempts at kinase inhibition produced compounds that were toxic in cell culture at concentrations required for activity, precisely because they inhibited essential kinases indiscriminately. The consensus in the field through the early 1990s was that ATP-competitive kinase inhibitors could not be made selective enough to be clinically useful.

This consensus was not irrational. It was based on the available structural and biochemical evidence. It was also wrong, for a reason that required more detailed structural understanding of kinase conformations than was available in the early 1990s: BCR-ABL has a unique inactive conformation that differs from most other kinases, and a small molecule that preferentially binds the inactive conformation can achieve the selectivity the field assumed was impossible. This was the insight, developed through years of iterative medicinal chemistry, that made imatinib possible.

The Philadelphia chromosome story illustrates an important feature of the regulatory framework described in Issue 004: GCP standards do not apply uniformly across all stages of drug development. The laboratory work of Nowell, Hungerford, Rowley, and the kinase biochemists was conducted under institutional research integrity standards, NIH grant compliance requirements, and the peer review process. None of it required IND authorization.

The transition to GCP-governed activity occurs at the IND application. For imatinib, that transition occurred when Druker's group was ready to begin dosing the first patients. At that point, all of the ICH-GCP E6 requirements we described in Issue 004 came into full effect: investigator qualifications, site monitoring, source data verification, informed consent procedures, adverse event reporting, and DSMB oversight.

This staged regulatory framework is intentional. Applying GCP standards to laboratory science would impose enormous administrative burden on basic research with no corresponding safety benefit, because no human participants are involved. The framework scales regulatory requirements to the level of human risk. When human risk begins, GCP begins.

Most oncology trial enrollment criteria run several pages. For precision-medicine trials, eligibility can require not just a confirmed diagnosis but a specific mutation, a documented molecular subtype, or the verified loss of a biomarker. The wrong molecular profile disqualifies a patient who otherwise looks identical to the one who qualifies. This is not a design flaw. It is the direct consequence of what this issue describes: the more precisely you understand the target, the more precisely you have to define who the drug is for.

That precision cuts both ways. A trial built around a rare mutation may be enrolling at three academic centers in the country. The cost and logistics of running a trial scale with every site added, so narrow protocols often mean narrow geographic reach. A qualifying patient may be four states from the nearest open site, seeing a community oncologist who has never heard of the trial.

This is where awareness becomes access. Every physician who knows a trial exists is a referral pathway. Every family member who understands what clinical trials actually are, and who they are designed for, is a potential link in a chain that might reach the one person who qualifies and has no other options. For a patient with a rare mutation and no approved treatment, a clinical trial is not a fallback. It is often the most medically supervised option available: experimental therapy plus the monitoring, safety reporting, and follow-up that standard care does not provide. The wider the awareness, the shorter the distance between an open slot and the person it was designed for. That is the gap this newsletter exists to close.

This is the first issue of a recurring web-companion section called For the Record. Each issue's For the Record breaks the takeaways down by reader: what the same story means depending on whether you are a general reader, a patient or caregiver, a clinician, or an advocate. The argument of the issue does not change. The action that follows from it does.

For the general reader: When you encounter a "hidden cancer cure" claim in your feed, you now have the Philadelphia chromosome timeline as a counter-example. Forty-one years of public, peer-reviewed work, every step visible, no suppression. Note that Gleevec did not cure CML either. It treated it, transforming a leukemia that killed most patients within five years into a chronic condition managed with daily oral medication. If a targeted therapy for any specific cancer subtype is announced tomorrow, the trail of evidence will look the same as the Gleevec trail. If the trail does not look like that, the claim is not what it seems.

For patients and caregivers: "Cancer" is not one disease. The most important question after a diagnosis is what specific subtype, driven by what specific molecular event. Targeted therapies exist for many subtypes and are increasingly the standard of care. Ask whether tumor molecular profiling has been done. Ask which targeted therapies, if any, are matched to the result. ClinicalTrials.gov lists trials searchable by disease subtype.

For clinicians: The Gleevec story changed how oncology evaluates a single-arm Phase II trial when the response rate is dramatic and the natural history of the disease is unambiguous. Single-agent imatinib in chronic phase CML was approved on a Phase II response rate, not a Phase III survival comparison. Subsequent confirmatory trials, including IRIS, validated the approval. The question of when a dramatic Phase II response rate is sufficient evidence for accelerated approval is the regulatory legacy of this case.

For advocates: The Gleevec story is the single most concrete proof that publicly funded basic research, sustained over decades, is what produces tomorrow's targeted therapies. NIH funding for CML basic science from 1960 through the late 1990s was the precondition for the targeted-therapy field. Defending that funding is the most direct way to ensure the next Gleevec is possible.

The science was ready by the mid-1990s. The compound existed. Druker's 1996 Nature Medicine paper showed it killed BCR-ABL-positive cells in vitro without harming normal cells. The next question was whether anyone would let him test it in a patient.

Novartis said no for six years. Issue 006 covers why, and what happened when they finally said yes. We meet Brian Druker, the oncologist who pursued the molecule that pharmaceutical industry consensus said could not exist. We watch the corporate inertia, the patient advocate pressure, and the single Phase I trial that changed cancer therapy.

Issue 006 drops Thursday, May 22.

Root to Rx is a clinical research literacy newsletter from Justin Yamashita. Most people see one part of the research pipeline. Justin has worked across all three: benchtop research during his Master's, clinical site execution, and global CRO oversight. Each Thursday, two tracks. Plain Talk explains how the system actually works. The Informed goes deeper for the curious.

If this is your first issue, the three foundation issues are: 003b (the Skeptic's Toolkit), 001 (why your distrust is rational), and 004 Plain Talk (how the drug development pipeline works).

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132(3438):1497.

Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.

Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306(5940):239-242.

Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079-1082.

Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. 1996;2(5):561-566.

Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome. Science. 1990;247(4944):824-830.

Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine. 2017;376(10):917-927.

Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib. Cancer Cell. 2002;2(2):117-125.

Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808-4817.

National Cancer Institute. Chronic Myeloid Leukemia Treatment (PDQ). cancer.gov

ICH. E6(R3) Guideline for Good Clinical Practice. International Council for Harmonisation, November 2023. ich.org

Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine. 2001;344(14):1031-1037.